Novartis to use Google technology for eye care

by The Associated Press

Swiss drug developer Novartis will team with technology giant Google to develop a "smart" contact lens that could improve some eye conditions or help diabetics manage their disease.

Terms of the agreement between the companies were not detailed in a statement released Tuesday by Novartis.

The drugmaker said its Alcon eye care division will license Google technology and work with a team from Google to develop a lens that uses microchips and miniaturized electronics. Novartis is focused on developing a contact lens that can provide a continuous measurement of in by measuring tear fluid.

It also said the lens has the potential to help restore the eye's natural auto focus on near objects for patients with who can no longer read without glasses. Presbyopia is a condition where the eye loses its ability to focus.

"This is a key step for us to go beyond the confines of traditional disease management, starting with the eye," Novartis CEO Joseph Jimenez said in a statement.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Patent talk: Google sharpens contact lens vision

Apr 16, 2014

(Phys.org) —A report from Patent Bolt brings us one step closer to what Google may have in mind in developing smart contact lenses. According to the discussion Google is interested in the concept of contact ...

Eli Lilly to buy part of Novartis for $5.4 bn

Apr 22, 2014

US pharmaceutical giant Eli Lilly said Tuesday it has reached an agreement to acquire the animal health division of Novartis of Switzerland for $5.4 billion (3.9 billion euros).

Novartis tries to make UK hospitals use $1000 drug

Apr 24, 2012

(AP) -- Drug maker Novartis says it is taking legal action in Britain to make hospitals use an eye drug that costs 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).

Recommended for you

New system targets germs in donated blood plasma

11 hours ago

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

India court blocks Bayer generic drug appeal

Dec 13, 2014

An Indian court has rejected German drug giant Bayer's bid to block a generic version of its blockbuster cancer treatment Nexavar by a local drugmaker, a move hailed by activists on Saturday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.